Ospemifene for the treatment of dyspareunia in postmenopausal women

Drugs of Today

Volumn 50, Issue 5, 2014, Pages 357-364

  Paton, David M ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Dyspareunia; FC 1271a; Ospemifene; Postmenopausal; SERM

Indexed keywords

AMFEBUTAMONE; BAZEDOXIFENE; ESTROGEN RECEPTOR ALPHA; FLUCONAZOLE; KETOCONAZOLE; OSPEMIFENE; PLACEBO; RIFAMPICIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; WARFARIN;

ARTICLE; BONE; BREAST CANCER; CANCER MODEL; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; COCARCINOGENESIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DYSPAREUNIA; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE GENITAL TRACT PARAMETERS; FOOD AND DRUG ADMINISTRATION; HUMAN; HYDROXYLATION; NONHUMAN; OSTEOPOROSIS; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRESCRIPTION; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TREATMENT DURATION; UROGENITAL SYSTEM; VAGINA ATROPHY; VAGINA PH;

DYSPAREUNIA; FC-1271A; OSPEMIFENE; POSTMENOPAUSAL; SERM;

BONE AND BONES; BREAST; DYSPAREUNIA; ENDOMETRIUM; FEMALE; HUMANS; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84901720052     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.5.2134451     Document Type: Article

References (34)

1. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013, 20(9): 888-902.
2. Ibe, C., Simon, J.A. Vulvovaginal atrophy: current and future therapies (CME). J Sex Med 2010, 7(3): 1042-50.
3. Rossouw, J.E., Anderson, G.L., Prentice, R.L. et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3): 321-33. (Pubitemid 34761611)
4. Lobo, R.A. Where are we 10 years after the Women's Health Initiative? J Clin Endocrinol Metab 2013, 98(5): 1771-80.
5. Ghazal, S., Pal, L. Perspective on hormone therapy 10 years after the WHI. Maturitas 2013, 76(3): 208-12.
6. Jordan, V.C. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 2007, 72(13): 829-42. (Pubitemid 47410069)
7. Hellmann-Blumberg, U., Taras, T.L., Wurz, G.T., DeGregorio, M.W. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene. Breast Cancer Res Treat 2000, 60(1): 63-70. (Pubitemid 30307466)
8. Qu, Q., Zheng, H., Dahllund, J. et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000, 141(2): 809-20. (Pubitemid 32250507)
9. Taras, T.L., Wurz, G.T., Hellmann-Blumberg, U., DeGregorio, M.W. Quantitative analysis of Z-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy] ethanol in human plasma using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999, 724(1): 163-71. (Pubitemid 29146032)
10. DeGregorio, M.W., Wurz, G.T., Taras, T.L., Erkkola, R.U., Halonen, K.H., Huupponen, R.K. Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol 2000, 56(6-7): 469-75.
11. Koskimies, P., Turunen, J., Lammintausta, R., Scheinin, M. Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in post-menopausal women. Int J Clin Pharmacol Ther 2013, 51(11): 861-7.
12. Highlights of prescribing information. Shionogi, Inc., February 2013. http://www.shionogi.com/pdf/PI/Osphena-Pl.pdf. Accessed April 15, 2014.
13. Koskimies, P., Katila, K., Lammintausta, R., Aaltonen, A.M., Vuorinen, J., Saarni, O., Scheinin, M. Oral bioavailability of ospemifene improves with food intake. Int J Clin Pharmacol Ther 2013, 51(10): 787-94.
14. Tolonen, A., Koskimies, P., Turpeinen, M., Uusitalo, J., Lammintausta, R., Pelkonen, O. Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact 2013, 28(3): 153-61.
15. Preston, R.A., Marbury, T.C., Wajima, T., Graham, S. The effect of renal and hepatic impairment on the pharmacokinetics of ospemifene, a tissue-selective estrogen agonist/antagonist. Am J Ther 2014, Advanced publication.
16. Lehtinen, T., Tolonen, A., Turpeinen, M. et al. Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene. Biopharm Drug Dispos 2013, 34(7): 387-95.
17. Turpeinen, M., Uusitalo, J., Lehtinen, T. et al. Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo. Int J Mol Sci 2013,14(7): 14064-75.
18. Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommendations for Clinical Evaluation. Food and Drug Administration, January 2, 2003. http://www.fda.gov/downloads/Drugs/DrugSafety/informationbyDrugClass/ UCM135338.pdf. Accessed April 15, 2014.
19. Cui, Y., Zong, H., Yan, H., Li, N., Zhang, Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med 2014, 11(2): 487-97.
20. Albertazzi, P., Sharma, S. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climacteric 2005, 8(3): 214-20. (Pubitemid 41224434)
21. Goldstein, S.R., Bachmann, G.A., Koninckx, P.R., Lin, V.H., Portman, D.J., Ylikorkala, O., Ospemifene Study Group. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014, 17(2): 173-82.
22. Kangas, L., Unkila, M. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids 2013, 78(12-13): 1273-80.
23. Mirkin, S., Komm, B.S. Tissue-selective estrogen complexes for postmenopausal women. Maturitas 2013, 76(3): 213-20.
24. Goldstein, S.R. Postmenopausal dyspareunia: has the Food and Drug Administration really helped? Menopause 2013, 20(6): 596-7.
25. Berga, S.L. Profile of ospemifene in the breast. Reprod Sci 2013, 20(10): 1130-6.
26. Komi, J., Heikkinen, J., Rutanen, E.M., Halonen, K., Lammintausta, R., Ylikorkala, O. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 2004, 18(3): 152-8. (Pubitemid 38328094)
27. Komi, J., Lankinen, K.S., DeGregorio, M. et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 2006, 24(4): 314-8. (Pubitemid 43992675)
28. Nappi, R.E., Kokot-Kierepa, M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric 2012, 15(1): 36-44.
29. Simon, J.A., Nappi, R.E., Kingsberg, S.A., Maamari, R., Brown, V. Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American post-menopausal women and their partners. Menopause 2014, 21(2): 137-42.
30. Nappi, R.E., Palacios, S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014, 17(1): 3-9.
31. Utian, W.H., Maamari, R. Attitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study. Climacteric 2014, 17(1): 29-36.
32. Sturdee, D.W., Panay, N., International Menopause Society Writing, G. Recommendations for the management of post-menopausal vaginal atrophy. Climacteric 2010, 13(6): 509-22.
33. Pickar, J.H. Emerging therapies for postmenopausal vaginal atrophy. Maturitas 2013, 75(1): 3-6.
34. Pal L. Systemic agents for focal symptoms: a promising pasture or a potential snare? Menopause 2014, 21(3): 213.